Recap: Intra-Cellular Therapies Q3 Earnings

Shares of Intra-Cellular Therapies ITCI remained unaffected after the company reported Q3 results.

Quarterly Results

Earnings per share decreased 25.40% year over year to ($0.79), which beat the estimate of ($1.00).

Revenue of $7,369,000 higher by 0.00% year over year, which beat the estimate of $5,860,000.

Looking Ahead

Intra-Cellular Therapies hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Nov 09, 2020

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/h8856x5f

Technicals

Company's 52-week high was at $43.56

52-week low: $8.51

Price action over last quarter: Up 29.21%

Company Overview

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.